CoChat

Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study

Open access
Reiman, Eric M., Arboleda-Velasquez, Joseph F., Quiroz, Yakeel T., Huentelman, Matthew J., Beach, Thomas G., Caselli, Richard J., Chen, Yinghua, Su, Yi, Myers, Amanda J., Hardy, John, Paul Vonsattel, Jean, Younkin, Steven G., Bennett, David A., De Jager, Philip L., Larson, Eric B., Crane, Paul K., Keene, C. Dirk, Kamboh, M. Ilyas, Kofler, Julia K., Duque, Linda, Gilbert, John R., Gwirtsman, Harry E., Buxbaum, Joseph D., Dickson, Dennis W., Frosch, Matthew P., Ghetti, Bernardino F., Lunetta, Kathryn L., Wang, Li-San, Hyman, Bradley T., Kukull, Walter A., Foroud, Tatiana, Haines, Jonathan L., Mayeux, Richard P., Pericak-Vance, Margaret A., Schneider, Julie A., Trojanowski, John Q., Farrer, Lindsay A., Schellenberg, Gerard D., Beecham, Gary W., Montine, Thomas J., Jun, Gyungah R., The Alzheimer’s Disease Genetics Consortium, Abner, Erin, Adams, Perrie M., Albert, Marilyn S., Albin, Roger L., Apostolova, Liana G., Arnold, Steven E., Asthana, Sanjay, Atwood, Craig S., Baldwin, Clinton T., Barber, Robert C., Barnes, Lisa L., Barral, Sandra, Becker, James T., Beekly, Duane, Bigio, Eileen H., Bird, Thomas D., Blacker, Deborah, Boeve, Bradley F., Bowen, James D., Boxer, Adam, Burke, James R., Burns, Jeffrey M., Cairns, Nigel J., Cantwell, Laura B., Cao, Chuanhai, Carlson, Chris S., Carlsson, Cynthia M., Carney, Regina M., Carrasquillo, Minerva M., Chui, Helena C., Cribbs, David H., Crocco, Elizabeth A., Cruchaga, Carlos, DeCarli, Charles, Dick, Malcolm, Doody, Rachelle S., Duara, Ranjan, Ertekin-Taner, Nilufer, Evans, Denis A., Faber, Kelley M., Fairchild, Thomas J., Fallon, Kenneth B., Fardo, David W., Farlow, Martin R., Ferris, Steven, Galasko, Douglas R., Gearing, Marla, Geschwind, Daniel H., Ghisays, Valentina, Goate, Alison M., Graff-Radford, Neill R., Green, Robert C., Growdon, John H., Hakonarson, Hakon, Hamilton, Ronald L., Hamilton-Nelson, Kara L., Harrell, Lindy E., Honig, Lawrence S., Huebinger, Ryan M., Hulette, Christine M., Jarvik, Gail P., Jin, Lee-Way, Karydas, Anna, Katz, Mindy J., Kauwe, John S. K., Kaye, Jeffrey A., Kim, Ronald, Kowall, Neil W., Kramer, Joel H., Kunkle, Brian W., Kuzma, Amanda P., LaFerla, Frank M., Lah, James J., Leung, Yuk Ye, Leverenz, James B., Levey, Allan I., Li, Ge, Lieberman, Andrew P., Lipton, Richard B., Lopez, Oscar L., Lyketsos, Constantine G., Malamon, John, Marson, Daniel C., Martin, Eden R., Martiniuk, Frank, Mash, Deborah C., Masliah, Eliezer, McCormick, Wayne C., McCurry, Susan M., McDavid, Andrew N., McDonough, Stefan, McKee, Ann C., Mesulam, Marsel, Miller, Bruce L., Miller, Carol A., Miller, Joshua W., Morris, John C., Mukherjee, Shubhabrata, Naj, Adam C., O’Bryant, Sid, Olichney, John M., Parisi, Joseph E., Paulson, Henry L., Peskind, Elaine, Petersen, Ronald C., Pierce, Aimee, Poon, Wayne W., Potter, Huntington, Qu, Liming, Quinn, Joseph F., Raj, Ashok, Raskind, Murray, Reisberg, Barry, Reisch, Joan S., Reitz, Christiane, Ringman, John M., Roberson, Erik D., Rogaeva, Ekaterina, Rosen, Howard J., Rosenberg, Roger N., Royall, Donald R., Sager, Mark A., Sano, Mary, Saykin, Andrew J., Schneider, Lon S., Seeley, William W., Smith, Amanda G., Sonnen, Joshua A., Spina, Salvatore, George-Hyslop, Peter St, Stern, Robert A., Swerdlow, Russell H., Tanzi, Rudolph E., Troncoso, Juan C., Tsuang, Debby W., Valladares, Otto, Van Deerlin, Vivianna M., Van Eldik, Linda J., Vardarajan, Badri N., Vinters, Harry V., Weintraub, Sandra, Welsh-Bohmer, Kathleen A., Wilhelmsen, Kirk C., Williamson, Jennifer, Wingo, Thomas S., Woltjer, Randall L., Wright, Clinton B., Wu, Chuang-Kuo, Yu, Chang-En, Yu, Lei, Zhao, Yi · 2020 · Nature Communications

Published version of a preprint

The DOI matches its Crossref record; 35 of the 36 references it cites were found in a registry or an index; 16 of the 40 sources its claims cite were checked for support.

Abstract

Each additional copy of the apolipoprotein E4 (APOE4) allele is associated with a higher risk of Alzheimer’s dementia, while the APOE2 allele is associated with a lower risk of Alzheimer’s dementia, it is not yet known whether APOE2 homozygotes have a particularly low risk. We generated Alzheimer’s dementia odds ratios and other findings in more than 5,000 clinically characterized and neuropathologically characterized Alzheimer’s dementia cases and controls. APOE2/2 was associated with a low Alzheimer’s dementia odds ratios compared to APOE2/3 and 3/3, and an exceptionally low odds ratio compared to APOE4/4, and the impact of APOE2 and APOE4 gene dose was significantly greater in the neuropathologically confirmed group than in more than 24,000 neuropathologically unconfirmed cases and controls. Finding and targeting the factors by which APOE and its variants influence Alzheimer’s disease could have a major impact on the understanding, treatment and prevention of the disease.

Overview

CoChat Summary

TL;DR

In a large clinically and neuropathologically characterized Alzheimer’s dementia case–control study, APOE2 homozygotes had an exceptionally low likelihood of Alzheimer’s dementia, especially compared with APOE4/4. The impact of APOE2 and APOE4 gene dose was greater in neuropathologically confirmed cases and controls than in neuropathologically unconfirmed groups.

Key findings

  • In the neuropathologically confirmed group, APOE2/2 had a significantly lower Alzheimer’s dementia OR than APOE2/3 (0.34, 95% CI 0.12–0.95), an extremely low OR versus APOE3/3 (0.13, 95% CI 0.05–0.36), and an exceptionally low OR versus APOE4/4 (0.004, 95% CI 0.001–0.014).
  • APOE4/4 versus APOE3/3 was associated with a much higher OR in the neuropathologically confirmed group (31.22, 95% CI 16.59–58.75) than in the neuropathologically unconfirmed group (10.70, 95% CI 9.12–12.56).
  • APOE2 allelic dose OR was lower in the neuropathologically confirmed group (0.38, 95% CI 0.30–0.48) than in the unconfirmed group (0.64, 95% CI 0.58–0.72), while APOE4 allelic dose OR was higher in the confirmed group (6.00, 95% CI 5.06–7.12) than in the unconfirmed group (3.43, 95% CI 3.26–3.60).
  • In neuropathologically confirmed cases with available onset ages, mean age at Alzheimer’s dementia onset ranged from 69.9 ± 6.1 years in APOE4/4 to 79.3 ± 9.0 years in the combined APOE2/3 and 2/2 group.

Methods

  • Primary analysis used the ADGC neuropathologically confirmed autopsy group: 5,007 brain donors, including 4,018 Alzheimer’s dementia cases and 989 cognitively unimpaired controls; post hoc comparisons used 23,857 neuropathologically unconfirmed clinical participants (10,430 cases, 13,426 controls) and a combined group of 28,864 participants (14,448 cases, 14,416 controls).
  • Alzheimer’s dementia ORs were computed for each APOE genotype and for APOE2/APOE4 allelic dose using logistic regression under a generalized linear model, with generalized estimating equations for clinical/combined groups to account for family structure; analyses were performed with and without adjustment for age and sex.
  • Additional analyses included ROC curves/AUCs for case–control classification, Kaplan–Meier curves for freedom from Alzheimer’s dementia, and linear regression for CERAD neuritic plaque scores and Braak tau tangle stage, including residual Braak effects after adjustment for CERAD score.

Limitations

  • The paper states that although the overall study was unusually large, there were relatively few APOE2 homozygotes, limiting statistical power; it also states that it cannot clarify whether the greater APOE effects in confirmed cases/controls are solely due to excluding neuropathologically misclassified cases/controls or also to brain-donation ascertainment bias.
  • The paper states that it cannot exclude an impact of differential disease onset, duration, or survival on Alzheimer’s dementia ORs and AD pathology measures, and that findings from non-Hispanic White groups cannot yet be extended to other ethnic and racial groups.
  • Evident from the text: this is a case–control/autopsy-based design, not a prospective cohort, so it does not provide absolute lifetime risk by APOE genotype; the paper also notes it does not provide information about preclinical AD, MCI, or primary diagnoses of other neurodegenerative disorders, and that onset-age estimates may be affected by lack of standardized prospective assessments.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41467-019-14279-8

Cites

35 of 36 references verified0 citation errors · 1 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Percent free from Alzheimer’s dementia. Kaplan–Meier curves were generated from Alzheimer’s dementia cases and cognitively unimpaired non-AD controls in the neuropathologically confirmed group. Y-axis represents the percentage of persons with each APOE genotype in the neuropathologically confirmed group who remained free from Alzheimer’s dementia. X-axis denotes age at death for controls and age at onset of cases, while replacing with age at death when age at onset was unavailable.
Fig. 1 Percent free from Alzheimer’s dementia. Kaplan–Meier curves were generated from Alzheimer’s dementia cases and cognitively unimpaired non-AD controls in the neuropathologically confirmed group. Y-axis represents the percentage of persons with each APOE genotype in the neuropathologically confirmed group who remained free from Alzheimer’s dementia. X-axis denotes age at death for controls and age at onset of cases, while replacing with age at death when age at onset was unavailable.CC BY · PubMed Central

Verification

Claims the paper makes

8 Valid · 3 Not valid · 9 Not checked · 56 Own results and interpretations

41 more claims

Create a free account to see all 76 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 19
  • Probably not a substantial claim. 18

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

9 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 36 references

Cited by

See all 473

Metadata

Authors
Reiman, E. M., Arboleda-Velasquez, J. F., Quiroz, Y. T., Huentelman, M. J., Beach, T. G., Caselli, R. J., Chen, Y., Su, Y., Myers, A. J., Hardy, J., Paul Vonsattel, J., Younkin, S. G., Bennett, D. A., De Jager, P. L., Larson, E. B., Crane, P. K., Keene, C. D., Kamboh, M. I., Kofler, J. K., Duque, L., Gilbert, J. R., Gwirtsman, H. E., Buxbaum, J. D., Dickson, D. W., Frosch, M. P., Ghetti, B. F., Lunetta, K. L., Wang, L.-S., Hyman, B. T., Kukull, W. A., Foroud, T., Haines, J. L., Mayeux, R. P., Pericak-Vance, M. A., Schneider, J. A., Trojanowski, J. Q., Farrer, L. A., Schellenberg, G. D., Beecham, G. W., Montine, T. J., Jun, G. R., The Alzheimer’s Disease Genetics Consortium, Abner, E., Adams, P. M., Albert, M. S., Albin, R. L., Apostolova, L. G., Arnold, S. E., Asthana, S., Atwood, C. S., Baldwin, C. T., Barber, R. C., Barnes, L. L., Barral, S., Becker, J. T., Beekly, D., Bigio, E. H., Bird, T. D., Blacker, D., Boeve, B. F., Bowen, J. D., Boxer, A., Burke, J. R., Burns, J. M., Cairns, N. J., Cantwell, L. B., Cao, C., Carlson, C. S., Carlsson, C. M., Carney, R. M., Carrasquillo, M. M., Chui, H. C., Cribbs, D. H., Crocco, E. A., Cruchaga, C., DeCarli, C., Dick, M., Doody, R. S., Duara, R., Ertekin-Taner, N., Evans, D. A., Faber, K. M., Fairchild, T. J., Fallon, K. B., Fardo, D. W., Farlow, M. R., Ferris, S., Galasko, D. R., Gearing, M., Geschwind, D. H., Ghisays, V., Goate, A. M., Graff-Radford, N. R., Green, R. C., Growdon, J. H., Hakonarson, H., Hamilton, R. L., Hamilton-Nelson, K. L., Harrell, L. E., Honig, L. S., Huebinger, R. M., Hulette, C. M., Jarvik, G. P., Jin, L.-W., Karydas, A., Katz, M. J., Kauwe, J. S. K., Kaye, J. A., Kim, R., Kowall, N. W., Kramer, J. H., Kunkle, B. W., Kuzma, A. P., LaFerla, F. M., Lah, J. J., Leung, Y. Y., Leverenz, J. B., Levey, A. I., Li, G., Lieberman, A. P., Lipton, R. B., Lopez, O. L., Lyketsos, C. G., Malamon, J., Marson, D. C., Martin, E. R., Martiniuk, F., Mash, D. C., Masliah, E., McCormick, W. C., McCurry, S. M., McDavid, A. N., McDonough, S., McKee, A. C., Mesulam, M., Miller, B. L., Miller, C. A., Miller, J. W., Morris, J. C., Mukherjee, S., Naj, A. C., O’Bryant, S., Olichney, J. M., Parisi, J. E., Paulson, H. L., Peskind, E., Petersen, R. C., Pierce, A., Poon, W. W., Potter, H., Qu, L., Quinn, J. F., Raj, A., Raskind, M., Reisberg, B., Reisch, J. S., Reitz, C., Ringman, J. M., Roberson, E. D., Rogaeva, E., Rosen, H. J., Rosenberg, R. N., Royall, D. R., Sager, M. A., Sano, M., Saykin, A. J., Schneider, L. S., Seeley, W. W., Smith, A. G., Sonnen, J. A., Spina, S., George-Hyslop, P. S., Stern, R. A., Swerdlow, R. H., Tanzi, R. E., Troncoso, J. C., Tsuang, D. W., Valladares, O., Van Deerlin, V. M., Van Eldik, L. J., Vardarajan, B. N., Vinters, H. V., Weintraub, S., Welsh-Bohmer, K. A., Wilhelmsen, K. C., Williamson, J., Wingo, T. S., Woltjer, R. L., Wright, C. B., Wu, C.-K., Yu, C.-E., Yu, L., & Zhao, Y.
Affiliations
  • Translational Genomics Research Institute (US)
  • Harvard University (US)
  • Banner Alzheimer’s Institute (US)
  • Mayo Clinic in Arizona (US)
  • University of Miami (US)
  • UCL Queen Square Institute of Neurology (GB)
  • Mayo Clinic in Florida (US)
  • Rush University Medical Center (US)
  • Kaiser Permanente Washington Health Research Institute (US)
  • University of Washington (US)
  • University of Pittsburgh (US)
  • Vanderbilt University (US)
  • Icahn School of Medicine at Mount Sinai (US)
  • Mayo Clinic (US)
  • Massachusetts General Hospital (US)
  • Indiana University Indianapolis (US)
  • Boston University (US)
  • University of Pennsylvania (US)
  • Case Western Reserve University (US)
  • Columbia University Irving Medical Center (US)
  • Stanford Medicine (US)
  • University of Kentucky (US)
  • The University of Texas Southwestern Medical Center (US)
  • Johns Hopkins University (US)
  • University of Michigan (US)
  • Duke University (US)
  • University of Wisconsin–Madison (US)
  • University of North Texas Health Science Center (US)
  • Northwestern University (US)
  • Massachusetts Eye and Ear Infirmary (US)
  • Swedish Medical Center (US)
  • University of California, San Francisco (US)
  • University of Kansas (US)
  • Washington University in St. Louis (US)
  • University of South Florida (US)
  • Fred Hutch Cancer Center (US)
  • University of Southern California (US)
  • University of California, Irvine (US)
  • University of California, Davis (US)
  • Baylor College of Medicine (US)
  • Mount Sinai Medical Center (US)
  • University of Alabama at Birmingham (US)
  • New York University (US)
  • University of California San Diego (US)
  • Emory University (US)
  • University of California, Los Angeles (US)
  • Brigham and Women's Hospital (US)
  • Children's Hospital of Philadelphia (US)
  • University of California Davis Medical Center (US)
  • Albert Einstein College of Medicine (US)
  • Brigham Young University (US)
  • Oregon Health & Science University (US)
  • Cleveland Clinic (US)
  • Pfizer (United States) (US)
  • University of Colorado Anschutz (US)
  • University of Toronto (CA)
  • The University of Texas at San Antonio Health Science Center (US)
  • Indiana University Hospital (US)
  • University of North Carolina at Chapel Hill (US)
  • Texas Tech University (US)
Corresponding author
Reiman, Eric M.
ORCID
Venue
Nature Communications
Published
2020-02-03
Volume
11
Issue
1
Pages
667-667
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3003860558
Cited by
473
References
36
Citations by year
2026: 57 · 2025: 73 · 2024: 92 · 2023: 69 · 2022: 74 · 2021: 64 · 2020: 44
FWCI
37.68
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • medRxiv (acceptedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • UA Campus Repository (The University of Arizona) (acceptedVersion, cc-by)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • UCL Discovery (University College London) (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
  • IUScholarWorks (Indiana University) (submittedVersion, cc-by)
  • Apollo (University of Cambridge) (submittedVersion, cc-by)
  • Apollo (cc-by)
Funders
U.S. Department of Health & Human Services | NIH | National Institute on Aging (RF1AG057519, P30-AG10161, R01AG15819, R01AG17917)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Complementary and alternative medicine › Medicinal Plants and Neuroprotection
Keywords
Alzheimer's disease, APOE ε4, apolipoprotein E, gene dosage, dementia risk, neuropathology
MeSH terms
Neuropathology, Aged, Aged, 80 and over, Alleles, Alzheimer Disease, Brain, Female, Genotype, Homozygote, Humans, Male, Middle Aged, Probability, Genetic Predisposition to Disease, Apolipoprotein E3, Apolipoprotein E4, Apolipoprotein E2, Genetic Association Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-01, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-01 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study. https://app.cochat.ai/papers/10.1038/s41467-019-14279-8
The paper
Reiman, E. M., Arboleda-Velasquez, J. F., Quiroz, Y. T., Huentelman, M. J., Beach, T. G., Caselli, R. J., Chen, Y., Su, Y., Myers, A. J., Hardy, J., Paul Vonsattel, J., Younkin, S. G., Bennett, D. A., De Jager, P. L., Larson, E. B., Crane, P. K., Keene, C. D., Kamboh, M. I., Kofler, J. K., . . . Zhao, Y. (2020). Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study. Nature Communications. https://doi.org/10.1038/s41467-019-14279-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.